Moderna's mRNA RSV Vaccine Approved by Health Canada for Seniors

Moderna, Inc., a pioneer in mRNA medicine development, revealed that Health Canada has authorized mRESVIA (mRNA vaccine for Respiratory Syncytial Virus) for active immunization aimed at preventing lower respiratory tract infections caused by respiratory syncytial virus (RSV) in adults aged 60 and above.

"Today's approval is an example of how our mRNA platform can help address significant public health challenges like RSV," said Stéphane Bancel, chief executive officer of Moderna. "As our second product approved by Health Canada, mRESVIA underscores our commitment to leveraging mRNA technology to protect vulnerable populations and contribute to a healthier future for Canadians."

mRESVIA is the sole RSV vaccine offered in a pre-filled syringe. This format provides a practical, pre-prepared solution that streamlines the vaccine administration process, conserving time for healthcare professionals and minimizing the likelihood of errors in administration. The availability of mRESVIA is expected in Canada by early 2025.

The National Advisory Committee on Immunization (NACI) advises that individuals in Canada who are 75 years and older, along with those aged 60 and over residing in nursing homes or other chronic care facilities, should receive vaccination against RSV. Adults aged 60 and older living in the community are advised to consider RSV vaccination as a personal choice after discussing it with their healthcare provider.